Completed PHASE2 INTERVENTIONAL 2-arm NCT02153502

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Sponsor: Avanir Pharmaceuticals

Conditions Depressive Disorder, Treatment-Resistant

Interventions AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination) Placebo

Updated 8 times since 2017 Last updated: May 11, 2017 Started: Jul 31, 2014 Primary completion: Feb 29, 2016 Completion: Feb 29, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Depressive Disorder, Treatment-Resistant and is currently completed. Avanir Pharmaceuticals leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jul 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Feb 2017 — Jul 2017 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Avanir Pharmaceuticals

Data source: Avanir Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Bellflower, United States , Birmingham, United States , Boston, United States , Bradenton, United States , Brooklyn, United States , Costa Mesa, United States , Decatur, United States , Denver, United States , Garden Grove, United States and 19 more locations